Maternal vaccination with capsular polysaccharide bioconjugates protects against murine Klebsiella pneumoniae neonatal sepsis.

Maternal vaccination with capsular polysaccharide bioconjugates significantly protects murine pups from lethal neonatal Klebsiella pneumoniae sepsis, with protection lasting at least six weeks.

• Why it matters: Klebsiella pneumoniae is a leading cause of neonatal sepsis and infectious deaths in young children, especially in low- and middle-income countries, and antibiotic resistance is increasing, highlighting the urgent need for effective preventative strategies.
• What they did: Researchers developed a murine model where dams were immunized with K1- and K2-conjugate vaccines during pregnancy, and offspring were tested for antibody levels and challenged with K. pneumoniae to assess protection.
• The result: Offspring of vaccinated dams showed significant protection from sepsis, with transferred antibodies persisting and remaining protective for at least six weeks, demonstrating vaccine efficacy in neonatal protection.